수의용 줄기세포 치료 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 동물별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Veterinary Stem Cell Therapy Market Summary

The global veterinary stem cell therapy market size was estimated at USD 856.0 million in 2025 and is projected to reach USD 1,642.8 million by 2033, growing at a CAGR of 9.0% from 2026 to 2033. The market is witnessing significant growth driven by the increasing incidence of chronic and degenerative conditions in pets, continuous advancements in stem cell therapy technologies, rising pet humanization, and a greater willingness among owners to invest in advanced veterinary care.

The market is further supported by the growing demand for advanced, disease-modifying therapies in veterinary care. Stem cell-based drugs provide the unique advantage of not only relieving clinical symptoms but also targeting the root cause of many chronic conditions. For instance, VET CELL TECH is helping drive this shift by building a strong pipeline using its own iPSC technology, which allows it to produce stem cell treatments on a large scale with reliable quality and smoother distribution. The company is developing regenerative therapies for major pet health problems like Feline Chronic Gingivostomatitis, chronic kidney disease in cats, atopic dermatitis in dogs, osteoarthritis, and several future conditions. Because these treatments are standardized, scalable, and designed for real clinical needs, they fill important gaps in care for older and chronically sick pets. This is expected to encourage more veterinarians to adopt stem cell therapies and increase overall spending on advanced regenerative care in the companion animal market.

In addition, initiatives undertaken to bring advanced, evidence-based regenerative therapies into mainstream veterinary care are significantly shaping market growth. For instance, according to an article published by The Indian Express, in June 2025, Gallant's stem cell therapy for a serious and painful condition in cats is expected to receive U.S. FDA approval in 2026. Getting this approval would be a big step forward, showing that the treatment is safe and truly works, which would boost confidence among veterinarians and pet owners. Once FDA-approved stem cell products become available, more clinics are likely to use them, investors may put more money into the field, and overall acceptance of regenerative treatments would grow-helping push the entire market forward.

Furthermore, rising pet spending is giving a strong boost to the market, because more pet owners now treat their animals like family and are willing to pay for advanced, high-quality medical care to keep them healthy. For instance, according to APPA, the rise in U.S. pet spending from USD 151.9 billion in 2024 to a projected USD 157 billion in 2025 shows that owners are consistently allocating more money toward premium and advanced veterinary care. This growing financial commitment directly supports the adoption of high-value treatments like stem cell therapy, which can be more expensive than traditional options but offer superior outcomes for chronic conditions such as osteoarthritis, dysplasia, and inflammatory diseases.

Global Veterinary Stem Cell Therapy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary stem cell therapy market report based on product, application, animal, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Autologous stem cell
• Allogeneic stem cell
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Small Animals
• Large Animals
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Orthopedics
• Soft Tissue Repair
• Other Applications
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals/Clinics
• Veterinary Academic & Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Animal
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Commodity Flow Analysis
  • 1.7.2. Model 2: Bottom-Up Analysis
  • 1.7.3. Model 3 Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Chronic Illness in Pets
    • 3.2.1.2. Technological Advancements in Stem Cell Therapy
    • 3.2.1.3. Supportive Initiatives by Government.
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Treatment Cost
    • 3.2.2.2. Lack of Awareness
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
  • 3.2.5. Technology Landscape
• 3.3. Pricing Analysis
• 3.4. Estimated Animal Population, By Key Species, Key Countries, 2025
• 3.5. Product Pipeline Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Veterinary Stem Cell Therapy Market: Product Estimates & Trend Analysis

• 4.1. Veterinary Stem Cell Therapy Market, By Product: Segment Dashboard
• 4.2. Veterinary Stem Cell Therapy Market, By Product Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Veterinary Stem Cell Therapy Market Estimates & Forecasts, by Product, 2021 - 2033 (USD Million)
• 4.4. Autologous Stem Cell
  • 4.4.1. Autologous Stem Cell Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.5. Allogeneic Stem Cell
  • 4.5.1. Allogeneic Stem Cell Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Veterinary Stem Cell Therapy Market: By Application Estimates & Trend Analysis

• 5.1. Veterinary Stem Cell Therapy Market, By Application: Segment Dashboard
• 5.2. Veterinary Stem Cell Therapy Market, By Application Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Veterinary Stem Cell Therapy Market Estimates & Forecasts, by Application, 2021 - 2033 (USD Million)
  • 5.3.1. Orthopedics
    • 5.3.1.1. Orthopedics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.2. Soft Tissue Repair
    • 5.3.2.1. Soft Tissue Repair Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.3. Other Applications
    • 5.3.3.1. Other Applications Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Veterinary Stem Cell Therapy Market: By Animal Estimates & Trend Analysis

• 6.1. Veterinary Stem Cell Therapy Market, By Animal: Segment Dashboard
• 6.2. Veterinary Stem Cell Therapy Market, By Animal Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Veterinary Stem Cell Therapy Market Estimates & Forecasts, by Animal, 2021 - 2033 (USD Million)
• 6.4. Small Animals
  • 6.4.1. Small Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Large Animals
  • 6.5.1. Large Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Veterinary Stem Cell Therapy Market: By End Use Estimates & Trend Analysis

• 7.1. Veterinary Stem Cell Therapy Market, By End Use: Segment Dashboard
• 7.2. Veterinary Stem Cell Therapy Market, By End Use Movement Analysis, 2025 & 2033 (USD Million)
• 7.3. Veterinary Stem Cell Therapy Market Estimates & Forecasts, by End Use, 2021 - 2033 (USD Million)
• 7.4. Veterinary Hospitals/Clinics
  • 7.4.1. Veterinary Hospitals/Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Veterinary Academic & Research Institutes
  • 7.5.1. Veterinary Academic & Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Stem Cell Therapy Market: By Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Boehringer Ingelheim International GmbH
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Vetherapy
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Vetstem, Inc.
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Ardent
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Cell Therapy Sciences
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Medrego
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. StemcellX
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Magellan Stem Cells
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. eQcell Inc
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Gallant
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives